Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ITCA 650 vs Glimepiride in Type 2 Diabetes
NCT01455883Phase 3Withdrawn
- Sponsor
- Intarcia Therapeutics
- Start
- Feb 2013
- Primary completion
- Jul 2014
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of exenatide in type 2 diabetes mellitus (T2DM), sponsored by Intarcia Therapeutics. Planned start Feb 2013; status: withdrawn.
02
Drugs
exenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01455883.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01455883.